Dementia is a clinical syndrome characterized by impairment of multiple higher cortical functions that include memory, orientation, thinking, comprehension, calculation, capacity for learning, language, judgment, executive function and visuo-spatial function. It is usually accompanied or preceded by deterioration in emotional control, social behavior or motivation.
Alzheimer's disease is the most common cause of dementia. Sporadic cases usually present after >60 year while familial types are rare and present in <60 year of age (early-onset dementia).
Short-term memory loss is the most common early symptom. Other spheres of cognitive impairment manifest after several years.
Statins appear to exert neuroprotective effects in diabetic prostate cancer patients receiving androgen deprivation therapy (ADT), with a recent study showing that the drug confers benefit for the risk of dementia. The benefit is greater with higher statin adherence and intensity.
Atrial fibrillation carries about a 30 percent excess risk of developing dementia, irrespective of cerebrovascular accidents (CVAs) and transient ischaemic attacks (TIAs), according to a systematic review and meta-analysis. Furthermore, the extent of involvement of the arrhythmia to cognitive injury appears to be greater than that related to CVA/TIA.
Concussion is associated with a substantial long-term risk of dementia in older adults, but the risk can be reduced modestly with the use of statins, a large population-based double cohort study has shown.
Verubecestat, an investigational beta-site amyloid precursor protein–cleaving enzyme 1 (BACE-1) inhibitor that blocks the production of amyloid-beta, does not improve cognition or daily function in patients with prodromal Alzheimer’s disease, results of a new study have shown.
A new combination product (AXS-07), which consists of the triptan rizatriptan and the NSAID* meloxicam, led to rapid and sustained pain relief than treatment with either component alone or placebo in patients with a history of inadequate response to prior acute migraine treatment, according to data from the MOMENTUM study released during the AAN 2020 Meeting.
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.